LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Aandelen Lijst・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Gesloten

SectorGezondheidszorg

34.23 -3.06

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

34.23

Max

34.23

Belangrijke statistieken
By Trading Economics
Inkomsten	11M 51M
Verkoop	39M 239M
K/W Sectorgemiddelde	11.36 110.024
EPS	1.08
Winstmarge	21.242
Werknemers	268
EBITDA	14M 73M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+65.47% upside

Dividenden
By Dow Jones
Volgende Winsten	24 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	387M 2.1B
Vorige openingsprijs	37.29
Vorige sluitingsprijs	34.23

Nieuwssentiment

By Acuity

50%

141 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

29.8 / N/A Steun & Weerstand

Harmony Biosciences Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 feb 2026, 17:37 UTC

Acquisities, Fusies, Overnames

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

21 feb 2026, 14:31 UTC

Acquisities, Fusies, Overnames

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb 2026, 05:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

20 feb 2026, 23:12 UTC

Acquisities, Fusies, Overnames

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Winsten

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Winsten

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Marktinformatie

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Acquisities, Fusies, Overnames

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20 feb 2026, 20:17 UTC

Marktinformatie

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20 feb 2026, 20:11 UTC

Marktinformatie

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20 feb 2026, 19:59 UTC

Marktinformatie

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20 feb 2026, 19:58 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20 feb 2026, 19:49 UTC

Marktinformatie

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20 feb 2026, 19:09 UTC

Marktinformatie

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20 feb 2026, 19:00 UTC

Marktinformatie

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20 feb 2026, 18:28 UTC

Marktinformatie

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20 feb 2026, 18:20 UTC

Marktinformatie

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20 feb 2026, 18:05 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 18:04 UTC

Marktinformatie

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20 feb 2026, 17:38 UTC

Marktinformatie

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20 feb 2026, 17:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 17:24 UTC

Marktinformatie

Correction to Treasury Yields Fall Market Talk

20 feb 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

20 feb 2026, 16:53 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 16:53 UTC

Marktinformatie

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20 feb 2026, 16:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 16:45 UTC

Marktinformatie

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

Peer Vergelijking

Prijswijziging

Harmony Biosciences Holdings Inc Prognose

Koersdoel

By TipRanks

65.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 48.25 USD 65.47%

Hoogste 55 USD

Laagste 42 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harmony Biosciences Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Harmony Biosciences Holdings Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

29.8 / N/ASteun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

141 / 351 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.